A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.
Bailey HH, et al.
Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. doi: 10.1007/s00280-004-0788-z. Epub 2004 Jun 15.
Cancer Chemother Pharmacol. 2004.
PMID: 15205914
Clinical Trial.